Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates

<p>Announced global Phase 1 clinical trial design of TERN-701 (allosteric BCR-ABL) for CML with patient screening anticipated in December 2023 and interim top-line data expected in the second half of 2024 Dosed first participant in Phase 1 clinical trial of TERN-601 (oral GLP-1) for obesity with top-line data expected in the second half of 2024 [&#8230;]</p>
<p>The post <a href="https://forextv.com/top-news/terns-pharmaceuticals-reports-third-quarter-2023-financial-results-and-corporate-updates/">Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>